drugset / Trial / NCT04255979
A Study of HY209 in Healthy Male Volunteers for Sepsis
RandomizedParallel-groupDouble-blindTreatment
Summary
A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after intravenous administration in healthy male volunteers
Timeline
- Start
- 2019-12-05
- Primary completion
- 2020-06-12
- Completion
- 2020-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 0.1 mg/kg | Intravenous |
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 0.2 mg/kg | Intravenous |
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 0.4 mg/kg | Intravenous |
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 0.8 mg/kg | Intravenous |
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 1.6 mg/kg | Intravenous |
| Subject | TAURODEOXYCHOLIC ACID | Small molecule | 3.2 mg/kg | Intravenous |